(NASDAQ: EIKN) Eikon Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.82%.
Eikon Therapeutics's earnings in 2026 is -$337,134,000.On average, 9 Wall Street analysts forecast EIKN's earnings for 2026 to be -$405,366,177, with the lowest EIKN earnings forecast at -$407,826,225, and the highest EIKN earnings forecast at -$382,337,086. On average, 9 Wall Street analysts forecast EIKN's earnings for 2027 to be -$402,467,221, with the lowest EIKN earnings forecast at -$450,839,148, and the highest EIKN earnings forecast at -$330,562,273.
In 2028, EIKN is forecast to generate -$325,539,222 in earnings, with the lowest earnings forecast at -$437,032,531 and the highest earnings forecast at -$210,512,979.